Europe

Report: U.K. biotech pulling ahead in Europe

Monday, July 27, 2015 12:26 PM

Over the past 10 years, the U.K. biotech sector has outperformed other European countries, raising $1.4 billion via IPOs and $2.4 billion in venture capital, according to a new report from life science market intelligence firm Evaluate and the U.K. BioIndustry Association (BIA). The rise in optimism has been most evident in 2014, with the momentum continuing into 2015.

More... »


All Party Parliamentary Group established to raise profile of U.K. life sciences sector

Wednesday, July 22, 2015 01:56 PM

The All Party Parliamentary Group (APPG) on Life Sciences has launched to raise awareness and understanding of the valuable contribution the life sciences sector provides to the health and the wealth of the U.K.

More... »


PHE drug development to transfer to new state-owned company

Friday, July 10, 2015 09:35 AM

Public Health England will transfer its drug development and production to a new company, Porton Biopharma. The transfer of Public Health England’s (PHE’s) clinical drug development and production capability into a stand-alone, state-owned biopharmaceutical limited company has been approved by the Secretary of State for Health.

More... »

Cancer Research U.K. invests $23.6 million in new major centers

Friday, June 26, 2015 09:16 AM

Cancer Research U.K. has launched Major Centers in Oxford, Manchester and Cambridge, with each receiving $7.7 million to boost their work in personalized cancer medicine and early detection research.

More... »

AveXis gains EMA Orphan designation from for spinal muscular atrophy treatment

Thursday, June 25, 2015 11:02 AM

The EMA has granted Orphan Drug designation to a gene transfer therapeutic currently in clinical development in the U.S. for the treatment of type 1 spinal muscular atrophy (SMA). AveXis, a gene therapy company developing treatments for rare and life-threatening genetic diseases, received Orphan Drug designation for SMA in the U.S. in Oct. 2014.

More... »

Redx Pharma launches third subsidiary, Redx Immunology

Monday, May 18, 2015 01:05 PM

Redx Pharma has launched its third subsidiary, Redx Immunology, which will focus on developing new therapies for disorders of the immune system.

More... »

Alexion Pharmaceuticals expands in Dublin, to add 200 jobs

Monday, May 11, 2015 03:19 PM

Alexion Pharmaceuticals will significantly expand its operations in Ireland by constructing the company's first ever biologics manufacturing facility outside the U.S. This $502.6 million, four-year project, which will be constructed at Alexion's College Park site in Blanchardstown, is expected to create approximately 200 additional full-time jobs on completion, bringing Alexion's total workforce in Ireland to almost 500.

More... »

Study: Clinical trial transparency improving

Thursday, May 7, 2015 12:23 PM

Transparency amongst industry-sponsored clinical trials continues to improve with results of 90% of trials on all new medicines approved by the EMA in 2012 disclosed within a 12-month timeframe, according to an Association of the British Pharmaceutical Industry (ABPI) study.

More... »

EMA tightens rules on 'revolving door' for committee members and experts

Thursday, May 7, 2015 12:21 PM

The EMA has updated its rules on declarations of interests for scientific committee members and experts. The updates further strengthen EMA’s policy by restricting involvement of experts in the scientific assessment of medicines if they plan to take up a job in the pharmaceutical industry. The updates also include a revised guide on how to complete the agency’s declaration of interest form.

More... »

Report: Transparency, cooperation help reduce high prices for new medicines

Friday, March 27, 2015 11:19 AM

As the number of new medicines introduced in Europe rises, governments are finding it increasingly difficult to afford them, according to a comprehensive study released today by the WHO Regional Office for Europe. The study illustrates the challenges for national health systems, with specific examples, and shows that few countries in the WHO European Region have mechanisms in place to evaluate the cost-effectiveness of new drugs; this hampers the value-assessment and decision-making processes.

More... »

`

CWWeekly

July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs